Fighting fungal infections with metals

23 September 2022

A Petri dish with red agar on which grows a fungal strand in the shape of the element symbol for platinum (Pt). Credit: CO-ADD

Each year, more than 1 billion people contract a fungal infection. Although they are harmless to most people, over 1.5 million patients die each year as a result of infections of this kind.

While more and more fungal strains are being detected that are resistant to one or more of the available drugs, the development of new drugs has come to a virtual standstill in recent years.

Today, only around a dozen clinical trials are underway with new active agents for the treatment of fungal infections. "In comparison with more than a thousand cancer drugs that are currently being tested on human subjects, this is an exceptionally small number," explains Dr. Angelo Frei of the Department of Chemistry, Biochemistry and Pharmacy at the University of Bern, lead author of the study.

The results have been published in the journal JACS Au.

Boosting antibiotics research with crowd sourcing

To encourage the development of anti-fungal and antibacterial agents, researchers at the University of Queensland in Australia have founded the Community for Open Antimicrobial Drug Discovery, or CO-ADD.

The ambitious goal of the initiative is to find new antimicrobial active agents by offering chemists worldwide the opportunity to test any chemical compound against bacteria and fungi at no cost. As Frei explains, the initial focus of CO-ADD has been on "organic" molecules, which mainly consist of the elements of carbon, hydrogen, oxygen and nitrogen, and do not contain any metals.

However, Frei, who is trying to develop new metal-based antibiotics with his research group at the University of Bern, has found that over 1,000 of the more than 300,000 compounds tested by CO-ADD contained metals.

"For most folks, when used in connection with the word 'people', the word metal triggers a feeling of unease. The opinion that metals are fundamentally harmful to us is widespread. However, this is only partially true. The decisive factor is which metal is used and in which form," explains Frei, who is responsible for all the metal compounds in the CO-ADD database.

Low toxicity demonstrated

In their new study, the researchers turned their attention to the metal compounds which showed activity against fungal infections. Here, 21 highly-active metal compounds were tested against various resistant fungal strains. These contained the metals cobalt, nickel, rhodium, palladium, silver, europium, iridium, platinum, molybdenum and gold.
"Many of the metal compounds demonstrated a good activity against all fungal strains and were up to 30,000 times more active against fungi than against human cells," explains Frei.

The most active compounds were then tested in a model organism, the larvae of the wax moth. The researchers observed that just one of the eleven tested metal compounds showed signs of toxicity, while the others were well tolerated by the larvae. In the next step, some metal compounds were tested in an infection model, and one compound was effective in reducing the fungal infection in larvae.

**Considerable potential for broad application**

Metal compounds are not new to the world of medicine: Cisplatin, for example, which contains platinum, is one of the most widely used anti-cancer drugs. Despite this, there is a long way to go before new antimicrobial drugs that contain metals can be approved.

"Our hope is that our work will improve the reputation of metals in medical applications and motivate other research groups to further explore this large but relatively unexplored field," says Frei.

"If we exploit the full potential of the periodic table, we may be able to prevent a future where we don't have any effective antibiotics and active agents to prevent and treat fungal infections."

**More information:** Angelo Frei et al, Metal Complexes as Antifungals? From a Crowd-Sourced Compound Library to the First In Vivo Experiments, *JACS Au* (2022). [DOI: 10.1021/jacsau.2c00308](https://pubs.acs.org/doi/10.1021/jacsau.2c00308)

---

Provided by University of Bern